Risk factors for monoclonal gammopathy of undetermined significance: a systematic review

被引:21
作者
Castaneda-Avila, Maira A. [1 ]
Ulbricht, Christine M. [1 ]
Epstein, Mara Meyer [1 ,2 ,3 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Populat & Quantitat Hlth Sci, Worcester, MA USA
[2] Univ Massachusetts, Sch Med, Meyers Primary Care Inst, 365 Plantat St,Suite 100, Worcester, MA 01605 USA
[3] Univ Massachusetts, Sch Med, Dept Med, 365 Plantat St,Suite 100, Worcester, MA 01605 USA
基金
美国国家卫生研究院;
关键词
MGUS; Risk factors; Systematic review; PRECEDES MULTIPLE-MYELOMA; SIGNIFICANCE MGUS; PRIOR AUTOIMMUNE; POOLED ANALYSIS; PREVALENCE; OBESITY; MORTALITY; CANCER; WHITE; METAANALYSIS;
D O I
10.1007/s00277-021-04400-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Monoclonal gammopathy of undetermined significance (MGUS), precursor of multiple myeloma, is an asymptomatic plasma cell disorder that overproduces serum monoclonal protein. Older age, male sex, black race, and family history of MGUS increase the risk of MGUS, yet other risk factors are known. We systematically reviewed observational epidemiological studies that examined sociodemographic, clinical, and behavioral risk factors for the development of MGUS. The protocol for this study was registered on the PROSPERO registry for systematic reviews. We identified epidemiological studies from PubMed and Scopus. Articles were limited to those written in English and published before February 2019. Five case-control and three cohort studies were eligible for data extraction. Studies evaluating factors associated with MGUS risk are limited, with conflicting conclusions regarding risk associated with obesity. Despite the limited research, a significant elevated risk for being diagnosed with MGUS was associated with several specific prior infections, inflammatory disorders, and smoking. The sparse existing literature suggests an increased risk of MGUS associated with several risk factors related to immune function. Further research is needed to explore the potential mechanisms underlying the development of MGUS and to confirm risk factors, both modifiable and non-modifiable.
引用
收藏
页码:855 / 863
页数:9
相关论文
共 50 条
  • [31] Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism
    Gregersen, Henrik
    Norgaard, Mette
    Severinsen, Marianne T.
    Engebjerg, Malene C.
    Jensen, Paw
    Sorensen, Henrik T.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (02) : 129 - 134
  • [32] Monoclonal gammopathy of undetermined significance: a consensus statement
    Berenson, James R.
    Anderson, Kenneth C.
    Audell, Robert A.
    Boccia, Ralph V.
    Coleman, Morton
    Dimopoulos, Meletios A.
    Drake, Matthew T.
    Fonseca, Rafael
    Harousseau, Jean-Luc
    Joshua, Douglas
    Lonial, Sagar
    Niesvizky, Ruben
    Palumbo, Antonio
    Roodman, G. David
    San-Miguel, Jesus F.
    Singhal, Seema
    Weber, Donna M.
    Zangari, Maurizio
    Wirtschafter, Eric
    Yellin, Ori
    Kyle, Robert A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (01) : 28 - 38
  • [33] Maculopathy in Patients with Monoclonal Gammopathy of Undetermined Significance
    Smith, Stephen J.
    Johnson, Mark W.
    Ober, Michael D.
    Comer, Grant M.
    Smith, Brian D.
    OPHTHALMOLOGY RETINA, 2020, 4 (03): : 300 - 309
  • [34] Monoclonal Gammopathy of Undetermined Significance: An Update for Nephrologists
    Parry, H. M.
    Pratt, G.
    Hutchison, C. A.
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2012, 19 (05) : 291 - 296
  • [35] Monoclonal Gammopathy of Undetermined Significance-Making It Understandable to Patients
    Rule, Pamela
    Brant, Jeannine M.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2013, 17 (06) : 614 - 619
  • [36] Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age
    Cherry, Benjamin M.
    Costello, Rene
    Zingone, Adriana
    Burris, Jason
    Korde, Neha
    Manasanch, Elisabet
    Kwok, Mary
    Annunziata, Christina
    Roschewski, Mark J.
    Engels, Eric A.
    Landgren, Ola
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (02) : 89 - 92
  • [37] Prognostic factors in malignant transformation of monoclonal gammopathy of undetermined significance
    Adami, F
    Bortolin, M
    Lestani, M
    Chilosi, M
    Semenzato, G
    LEUKEMIA & LYMPHOMA, 2002, 43 (08) : 1713 - 1714
  • [38] Monoclonal gammopathy of undetermined significance and bone health outcomes: a systematic review and exploratory meta-analysis
    Veronese, Nicola
    Luchini, Claudio
    Solmi, Marco
    Sergi, Giuseppe
    Manzato, Enzo
    Stubbs, Brendon
    JOURNAL OF BONE AND MINERAL METABOLISM, 2018, 36 (01) : 128 - 132
  • [39] Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults
    Guerard, Emily J.
    Tuchman, Sascha A.
    CLINICS IN GERIATRIC MEDICINE, 2016, 32 (01) : 191 - +
  • [40] Identifying monoclonal gammopathy of undetermined significance in electronic health data
    Epstein, Mara Meyer
    Saphirak, Cassandra
    Zhou, Yanhua
    LeBlanc, Candace
    Rosmarin, Alan G.
    Ash, Arlene
    Singh, Sonal
    Fisher, Kimberly
    Birmann, Brenda M.
    Gurwitz, Jerry H.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (01) : 69 - 76